Two clinical trials have applied the nAChR agonist nicotine by transdermal patch (ClinicalTrials.gov Identifier: NCT01560754) or nasal spray (ClinicalTrials.gov Identifier: NCT03865121) in the treatment of PD, but the trial results are unclear [56]. Here, CHRNA4 is linked to Parkinson disease.